How to buy Esperion Therapeutics stock (ESPR)

Esperion Therapeutics is a drug manufacturers - specialty & generic business based in the US. Esperion Therapeutics shares (ESPR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.18 – a decrease of 3.33% over the previous week. Esperion Therapeutics employs 240 staff and has a trailing 12-month revenue of around $295.5 million.

Our top picks for where to buy Esperion Therapeutics stock

Buy Esperion Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Esperion Therapeutics stock price (NASDAQ: ESPR)

Use our graph to track the performance of ESPR stocks over time.

Esperion Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$2.18
52-week range	$1.58 - $3.94
50-day moving average more info button	$2.39
200-day moving average more info button	$2.24
Wall St. target price	$7.51
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.67

Is it a good time to buy Esperion Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Esperion Therapeutics price performance over time

Historical closes compared with the close of $2.16 from 2024-12-18

1 week (2024-12-13)	-4.00%
1 month (2024-11-20)	-10.37%
3 months (2024-09-20)	28.57%
6 months (2024-06-20)	-5.68%

1 year (2023-12-20)	-4.85%
2 years (2022-12-20)	-65.38%
3 years (2021-12-20)	5.16
5 years (2019-12-20)	53.9

Is Esperion Therapeutics stock undervalued or overvalued?

Valuing Esperion Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Esperion Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Esperion Therapeutics's EBITDA

Esperion Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $16.5 million.

The EBITDA is a measure of a Esperion Therapeutics's overall financial performance and is widely used to measure a its profitability.

Esperion Therapeutics financials

Revenue TTM	$295.5 million
Gross profit TTM	$-70,419,000
Return on assets TTM	3.84%
Return on equity TTM	-260.79%
Profit margin	-29.37%
Book value	$-1.89
Market Capitalization more info button	$425.6 million

TTM: trailing 12 months

Esperion Therapeutics share dividends

We're not expecting Esperion Therapeutics to pay a dividend over the next 12 months.

Have Esperion Therapeutics's shares ever split?

Esperion Therapeutics's shares were split on a 1:6 basis on 10 June 2013 . So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Esperion Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Esperion Therapeutics shares which in turn could have impacted Esperion Therapeutics's share price.

Esperion Therapeutics share price volatility

Over the last 12 months, Esperion Therapeutics's shares have ranged in value from as little as $1.58 up to $3.94. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Esperion Therapeutics's is 0.954. This would suggest that Esperion Therapeutics's shares are less volatile than average (for this exchange).

Esperion Therapeutics overview

Esperion Therapeutics, Inc. , a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co. , Ltd; and Daiichi Sankyo Europe GmbH.

Frequently asked questions

null
What percentage of Esperion Therapeutics is owned by insiders or institutions?
Currently 0.498% of Esperion Therapeutics shares are held by insiders and 66.34% by institutions. How many people work for Esperion Therapeutics?
Latest data suggests 240 work at Esperion Therapeutics. When does the fiscal year end for Esperion Therapeutics?
Esperion Therapeutics's fiscal year ends in December. Where is Esperion Therapeutics based?
Esperion Therapeutics's address is: 3891 Ranchero Drive, Ann Arbor, MI, United States, 48108 What is Esperion Therapeutics's ISIN number?
Esperion Therapeutics's international securities identification number is: US29664W1053 What is Esperion Therapeutics's CUSIP number?
Esperion Therapeutics's Committee on Uniform Securities Identification Procedures number is: 29664W105